Basic Mirtazapine Information

• INN (International Nonproprietary Name): Mirtazapine
• Brand Names Available In United Kingdom: Zispin; Mirtazapine Teva (orodispersible tablets commonly supplied in 15 mg, 30 mg and 45 mg).
• ATC Code: N06AX11
• Forms & Dosages: Film-coated or standard tablets 7.5 mg (rare), 15 mg, 30 mg, 45 mg; orodispersible tablets 15 mg, 30 mg, 45 mg; oral solution not universally available; no injectable forms for routine clinical use.
• Manufacturers In United Kingdom: Manufactured and supplied by multiple generic producers including Teva, Sandoz, Mylan, HEXAL and original developer Organon (local packaging/repacking common).
• Registration Status In United Kingdom: MHRA-approved; included in NHS formularies; prescription-only medicine.
• OTC / Rx Classification: Prescription Only (Rx) — not available over the counter in routine practice.

Everyday Use & Best Practices

Morning Vs Evening Dosing

Take mirtazapine at the same time each day as advised by the prescriber, usually at bedtime.

Mirtazapine is sedating and NHS guidance typically recommends once-daily dosing at night to aid sleep and reduce daytime drowsiness.

The standard adult dose range is 15–45 mg once daily at night, with many courses starting at 15 mg.

If morning grogginess persists despite night dosing, speak to your GP or pharmacist rather than stopping suddenly.

Stopping abruptly can cause withdrawal symptoms; tapering under clinical supervision is recommended.

Therapeutic effects on sleep can appear within 1–2 weeks, with mood benefits often taking 4–6 weeks.

For insomnia alone, clinicians sometimes use lower doses; any change should be discussed with the prescriber.

Taking With Or Without Meals (UK Diet Habits)

Mirtazapine can be taken with or without food, which makes it convenient after a typical evening meal.

In the UK, evening meals are often the heaviest, and taking the tablet after food may reduce stomach upset for sensitive patients.

For orodispersible tablets such as Zispin or Mirtazapine Teva, place the tablet on the tongue and allow it to dissolve; no water is required.

Store tablets in the original packaging at 15–30°C and keep them out of reach of children.

• Quick Dosing Do's: Take at bedtime; follow the prescribed dose (15–45 mg qhs); let orodispersible tablets dissolve.
• Quick Dosing Don'ts: Do not double up if you miss a dose; do not stop suddenly; avoid alcohol when starting.

• Checklist For Your GP/Pharmacist: current medicines including antidepressants, alcohol intake, pregnancy/breastfeeding status, history of bipolar or seizures, liver or kidney problems.

Safety Priorities

Who Should Avoid It (MHRA Warnings)

Mirtazapine is contraindicated in patients with known hypersensitivity to mirtazapine or any excipients.

Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI is an absolute contraindication.

Caution is required for people with a history of bipolar disorder or recent mania, as antidepressants can precipitate mania.

Seizure disorders, severe hepatic or renal impairment, recent myocardial infarction and certain cardiac conditions call for careful review before prescribing.

Elderly patients should usually start at a lower dose (7.5–15 mg) and be monitored for sedation, orthostatic hypotension and falls.

Allergy to an excipient is also a contraindication; always check product leaflets or ask a pharmacist.

When in doubt, request review by the prescriber and consider specialist referral for complex medical histories.

Activities To Limit (Driving, Work Safety)

Mirtazapine commonly causes somnolence, dizziness and slowed reaction times, especially when starting or after dose increases.

UK drivers must self-assess their fitness to drive and refrain from driving if reaction time or alertness is impaired; this is a legal and safety issue.

Avoid heavy machinery, night-shift driving and safety-critical roles until the medication’s effects are known.

Alcohol potentiates sedation and should be limited or avoided while trialling the drug.

• Red Flags Prompting Urgent Review: severe drowsiness, fainting, chest pain, blackouts, new or worsening suicidal thoughts.

Dosage & Adjustments

General Regimen (NHS Guidance)

Typical NHS prescribing for major depressive disorder is 15–45 mg once daily at night, often starting at 15 mg.

Therapeutic benefits for sleep may be noticed within 1–2 weeks, with full antidepressant response commonly by 4–6 weeks.

For insomnia or appetite stimulation, clinicians sometimes use lower doses (7.5–15 mg) off-label, but this should be prescriber-led.

Mirtazapine is a prescription-only medicine; follow-up and monitoring are arranged via GP or psychiatry clinics.

If a dose is missed, take it as soon as remembered unless it is near the next scheduled dose; do not double the next dose.

In the event of suspected overdose, seek emergency care because of potential CNS and cardiac effects.

Special Cases (Elderly, Comorbidities)

Start elderly patients at the lower end (7.5–15 mg) and titrate slowly to reduce sedation and orthostatic hypotension risk.

For hepatic impairment, begin at the lowest dose and increase cautiously due to higher exposure to active drug.

Severe renal impairment warrants close monitoring though mild–moderate impairment often requires no routine dose change.

Use in children and adolescents is not routinely recommended; specialist review is necessary for off-label prescriptions.

• Typical Starting/Titration Guide: Start 15 mg qhs; review at 2–4 weeks; consider 30 mg if inadequate; maximum commonly 45 mg qhs under supervision.

• Monitoring Checklist: blood pressure, weight, mood/suicidal ideation, hepatic function if indicated, falls risk in older adults.

User Testimonials

Positive Reports From UK Patients

Many UK patients report improved nocturnal sleep within days after starting mirtazapine, which can help break the cycle of sleeplessness and low mood.

Patient.info threads and local NHS support groups often describe clearer sleep and gradual mood stabilisation over several weeks.

Some people appreciate that mirtazapine tends to cause fewer sexual side effects than several SSRIs, which can aid adherence.

Reports also highlight improved appetite where weight loss was a concern, for example in palliative care or severe depression.

A typical anecdote: a patient prescribed 15 mg at night noticed better sleep within a week and mood improvement by four weeks.

Common Challenges (Patient.info, NHS Forums)

Commonly reported drawbacks include daytime drowsiness, dry mouth and weight gain, which are important to monitor with the GP.

Some patients experience vivid dreams or transient anxiety in the first couple of weeks of treatment.

Online forums recommend tracking appetite and weight and discussing dosage adjustments rather than stopping suddenly.

• Positives: sleep improvement, appetite increase, lower sexual side effects compared with some SSRIs.
• Negatives: sedation, weight gain, dry mouth, occasional vivid dreams.

• Checklist For GP Discussion: sleep pattern changes, appetite/weight shifts, daytime sleepiness, mood trajectory, side-effect tolerability.

Buying Guide

Pharmacy Sources (Boots, LloydsPharmacy, Superdrug)

Mirtazapine is prescription-only in the UK and is supplied via NHS and private pharmacies including Boots, LloydsPharmacy and Superdrug as well as NHS-approved online providers.

Generic options such as Mirtazapine Teva, Mirtazapine Sandoz and Mirtazapine Mylan are commonly dispensed; orodispersible 15/30/45 mg forms are widely available.

Pharmacists can provide counselling on dosing, storage and side-effect management and can perform a Medicines Use Review when required.

In our online pharmacy, mirtazapine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Price Comparison (NHS Prescription Charge Vs Private)

In England a standard NHS prescription charge applies per item unless the patient is exempt; prescriptions are free in Scotland, Wales and Northern Ireland.

Private prescriptions cost vary, but generics are usually cheaper than branded products.

For long-term treatment, prescription prepayment certificates (PPCs) can reduce costs — discuss options with the GP practice.

Avoid unregulated online sellers; use MHRA-endorsed pharmacies and check pharmacist credentials and secure payment/dispensing details.

What’s Inside & How It Works

Ingredients Overview

The active ingredient in all products is the international nonproprietary name mirtazapine.

Excipients vary by manufacturer (Teva, Sandoz, HEXAL, Mylan); absolute allergy to any excipient is a contraindication.

Available formats in the UK commonly include orodispersible tablets and standard tablets in 15 mg, 30 mg and 45 mg strengths.

Store mirtazapine at 15–30°C, protect from moisture and light, and keep in original packaging away from children.

There are no injectable formulations for routine clinical use listed in standard product information.

Mechanism Basics Explained Simply

Mirtazapine is classified as a tetracyclic antidepressant (ATC N06AX11) that increases noradrenergic and serotonergic transmission indirectly.

It antagonises central presynaptic alpha-2 autoreceptors and heteroreceptors, which boosts release of noradrenaline and serotonin.

It also blocks certain serotonin receptors (5-HT2 and 5-HT3), which helps mood and reduces some common SSRI-related side effects such as sexual dysfunction.

The strong antihistaminic effect explains its sedative properties and appetite stimulation, which are often therapeutically useful.

• Excipient-Check Tips: check the patient information leaflet or ask the pharmacist if you have known allergies or sensitivities.

Main Indications

Approved Uses (MHRA Listing)

The MHRA-approved primary indication for mirtazapine is major depressive disorder in adults.

The usual adult dose for depression is 15–45 mg once daily at night, with clinicians guided by NICE and local NHS formularies.

Mirtazapine is frequently chosen when depressive symptoms include significant insomnia or weight loss because of its sedative and appetite-stimulating properties.

Treatment for depression typically continues for 6–12 months after remission to reduce relapse risk, with gradual tapering on discontinuation.

Off-Label Uses In UK Clinics

UK clinicians sometimes prescribe mirtazapine off-label for anxiety with insomnia, as an appetite stimulant in palliative care, or adjunct therapy in treatment-resistant depression.

Such off-label use should be clearly documented and monitored by the treating clinician.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

Alcohol increases sedation with mirtazapine and should be avoided or minimised when starting treatment.

There are no major food-binding interactions, so normal meals are acceptable with dosing.

Large amounts of caffeine from tea or coffee may counteract the sedative effect and impair sleep, which negates one of the drug’s benefits for insomnia.

Advise patients to consider abstaining from alcohol during the initial trial period and to moderate caffeine intake in the evenings.

Drug Conflicts (MHRA Yellow Card Reports)

Do not combine mirtazapine with MAOIs or start it within 14 days of stopping an MAOI due to serious interactions.

Caution is needed with other CNS depressants such as benzodiazepines, opioids and some antipsychotics due to additive sedation.

Drugs affecting CYP metabolism may alter mirtazapine levels; clinical monitoring is advised when co-prescribing such agents.

While not a prominent QT-prolonging agent, monitoring is prudent in overdose or when co-prescribed with certain cardiac drugs.

• High-Risk Drugs To Avoid Or Review: MAOIs, strong CYP inhibitors/inducers, other sedatives, certain cardiac medications.

Suspected adverse reactions should be reported through the MHRA Yellow Card scheme.

Latest Evidence & Insights

Key UK & EU Studies 2022–2025

Recent UK and EU literature between 2022 and 2025 has concentrated on mirtazapine’s comparative effectiveness for insomnia comorbid with depression and tolerability versus SSRIs.

Meta-analyses consistently report quicker sleep benefits and lower sexual dysfunction rates compared with several SSRIs, but higher rates of weight gain and daytime sedation.

Observational studies emphasise cautious titration in older adults to minimise falls and orthostatic hypotension.

Palliative and oncology research continues to explore its appetite-stimulating benefits in cachexia and chemotherapy-related anorexia.

Practical Takeaways For Patients

Expect sleep improvement early, usually within 1–2 weeks, and monitor weight at baseline and during follow-up.

If switching from SSRIs or SNRIs, coordinate closely with the prescriber to reduce the small risk of serotonin-related complications.

Overall evidence supports mirtazapine as a useful option when sleep disturbance or low appetite are prominent symptoms in depression.

• Key Findings Summary: faster sleep benefits; fewer sexual side effects; monitor weight and sedation; careful dosing in older adults.

Alternative Choices

NHS Prescribing Alternatives With Pros/Cons Checklist

Common NHS alternatives include SSRIs (sertraline, escitalopram, fluoxetine), SNRIs (venlafaxine, duloxetine) and atypical agents such as trazodone or bupropion.

SSRIs are well-established and generally less sedating, but sexual dysfunction is a common trade-off.

Bupropion has lower sexual side effects and a more activating profile, which may be undesirable with insomnia.

Trazodone is sedating and sometimes preferred for insomnia but has its own side-effect spectrum.

• Pros/Cons Checklist: SSRIs — pros: evidence base; cons: sexual side effects. Bupropion — pros: energising; cons: insomnia risk. Trazodone — pros: sedating; cons: hypotension, priapism (rare).

Choosing Based On Symptoms

When insomnia and low appetite are the dominant issues, mirtazapine may be preferable for its sedative and appetite-stimulating properties.

If anxiety without insomnia or weight concerns predominates, an SSRI might be selected instead.

Discuss personal priorities, side-effect tolerance and NHS formulary availability with the GP when deciding on an antidepressant.

Regulation Snapshot

MHRA Approval & NHS Prescribing Framework

Mirtazapine is MHRA-approved and is a prescription-only medicine across the UK.

It appears on NHS formularies and is prescribed by GPs, psychiatrists and hospital specialists according to local guidelines.

Manufacturers and generics available in the UK include Zispin (brand), Mirtazapine Teva and other authorised generics by Teva, Sandoz and Mylan.

ATC classification is N06AX11, reflecting its tetracyclic antidepressant status.

Reporting And Safety Surveillance

Adverse events should be reported to the MHRA via the Yellow Card scheme to support ongoing pharmacovigilance.

Pharmacies must follow legal prescription and dispensing requirements and support monitoring plans arranged by GP practices.

For cross-border purchases note that product packaging and formulations can differ by country; always check patient information leaflets and licences.

FAQ Section

3–4 Common UK Patient Questions

Q1: Will mirtazapine make me sleepy all day?

A1: Many patients find nocturnal sleep improves; daytime drowsiness is common early but usually decreases; dosing at night reduces daytime effects.

Q2: Will I gain weight?

A2: Increased appetite and weight gain are commonly reported; baseline and follow-up weight checks are advisable, and discuss diet or dose adjustments with your GP.

Q3: Can I drink alcohol?

A3: Best avoided or minimised while starting due to increased sedation and safety concerns.

Q4: Is it safe to stop suddenly?

A4: No — stopping abruptly can cause withdrawal symptoms; tapering under GP supervision is recommended.

• What To Ask At Your GP Appointment: target symptoms, expected timeline, plan for side effects, monitoring schedule and cost/prescription queries.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Pharmacists in Boots, LloydsPharmacy and other community pharmacies will confirm indication, dosing (commonly 15–45 mg at night) and check for contraindications such as recent MAOI use.

Advice covers storage at 15–30°C, avoidance of alcohol, managing dry mouth and recognising red-flag symptoms like worsening mood or suicidal thoughts.

Request a Medicines Use Review if there are concerns about adherence or side effects, and arrange follow-up with the prescriber.

NHS Patient Support Advice

Follow NHS and GP advice for baseline checks such as weight and blood pressure and arrange follow-up appointments at around 2–4 weeks to assess response and tolerability.

Monitoring for mood changes and suicidal ideation is especially important during initiation and dose changes.

For prescription cost concerns, ask about prescription prepayment certificates or exemptions; in Scotland, Wales and Northern Ireland prescriptions are free.

• Pharmacist Counselling Checklist: indication, dose, storage, contraindications, sedation risks, alcohol advice, follow-up timing.

• Patient Follow-Up Timetable: initial check 2 weeks; review 4 weeks; ongoing reviews at 3 months and per clinical need.

Delivery Across United Kingdom